Noninvasive Real-Time Glucose Monitoring Is in the Near Future
Authors' conclusion
Our results show promise as potentially the first noninvasive technology.
Study context
- Population
- Subjects with T2D, T1D, nondiabetic pregnant subjects and nondiabetic subjectsSubjects with T2D 6 · T1D 28 · nondiabetic pregnant subjects 10 · nondiabetic subjects 31
- Participants
- 75 subjects
- Comparison
- Noninvasive GWave device vs capillary blood glucose
- Outcome
- Accuracy vs reference capillary blood glucose (Clarke Error Grid; mean absolute relative difference)
Performance
As reported in the abstract
Values in Zone A of the Clarke Error Grid
97%
Values in Zone B of the Clarke Error Grid
3%
Mean absolute relative difference from reference blood glucose
6.7%
Further findings
Reproducibility between two independent Gen III GWave devices
- Reproducibility between sensors, R2
- 0.95
- Values within Zone A
- 100%
Accuracy during insulin-induced hypoglycaemia
- Gen III sensor tightly followed capillary glucose down to 42 mg/dL (2.3 mmol/L); Continuous glucose monitoring (CGM) measurements from two different CGM only converged with GWave and capillary readings after 90 min of decreasing glucose
Original publication
Noninvasive Real-Time Glucose Monitoring Is in the Near Future. Diabetes Technol Ther. Published 17 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →